Clinical efficacy of selective JAK1 inhibition and transcriptome analysis of chronic discoid lupus erythematosus
J Eur Acad Dermatol Venereol
.
2022 Apr;36(4):e308-e310.
doi: 10.1111/jdv.17839.
Epub 2021 Dec 27.
Authors
A Calugareanu
1
2
,
C Grolleau
2
3
,
H Le Buanec
2
,
F Chasset
4
,
M Jachiet
2
3
,
M Battistella
2
5
,
M Bagot
2
3
,
D Jullien
1
,
S Poutrel
6
,
J-D Bouaziz
2
3
,
B Ben Said
1
Affiliations
1
Severe Cutaneous Adverse Reaction (SCAR) Regional Center and Dermatology Department, CHU Lyon Centre, Hospices Civils de Lyon (HCL), Lyon, France.
2
INSERM U976, Hôpital Saint-Louis, Paris, France.
3
Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
4
Dermatology Department, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
5
Pathology Department, AP-HP, Hôpital Saint-Louis, Paris, France.
6
Internal Medicine Department, CHU Lyon Centre, Hospices civils de Lyon (HCL), Lyon, France.
PMID:
34839559
DOI:
10.1111/jdv.17839
No abstract available
Publication types
Letter
MeSH terms
Gene Expression Profiling
Humans
Janus Kinase 1* / antagonists & inhibitors
Lupus Erythematosus, Discoid* / drug therapy
Treatment Outcome
Substances
JAK1 protein, human
Janus Kinase 1